Dose Modification of Subcutaneous Tocilizumab in Patients with Rheumatoid Arthritis
| Medienart: |
Artikel |
|---|
| Erscheinungsjahr: |
2020 |
|---|---|
| Erschienen: |
2020 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:13 |
|---|---|
| Enthalten in: |
American health & drug benefits - 13(2020), 2 vom: 06. Mai, Seite 72-73 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Best, Jennie H [VerfasserIn] |
|---|
| Themen: |
|---|
| Anmerkungen: |
Date Revised 28.09.2020 published: Print Citation Status PubMed-not-MEDLINE |
|---|
| Förderinstitution / Projekttitel: |
|
|---|
| PPN (Katalog-ID): |
NLM313002053 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM313002053 | ||
| 003 | DE-627 | ||
| 005 | 20231225145631.0 | ||
| 007 | tu | ||
| 008 | 231225s2020 xx ||||| 00| ||eng c | ||
| 028 | 5 | 2 | |a pubmed24n1043.xml |
| 035 | |a (DE-627)NLM313002053 | ||
| 035 | |a (NLM)32724501 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Best, Jennie H |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Dose Modification of Subcutaneous Tocilizumab in Patients with Rheumatoid Arthritis |
| 264 | 1 | |c 2020 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ohne Hilfsmittel zu benutzen |b n |2 rdamedia | ||
| 338 | |a Band |b nc |2 rdacarrier | ||
| 500 | |a Date Revised 28.09.2020 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status PubMed-not-MEDLINE | ||
| 650 | 4 | |a Journal Article | |
| 700 | 1 | |a Abbass, Ibrahim |e verfasserin |4 aut | |
| 700 | 1 | |a Tominna, Lenore |e verfasserin |4 aut | |
| 700 | 1 | |a Reiss, William |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t American health & drug benefits |d 2008 |g 13(2020), 2 vom: 06. Mai, Seite 72-73 |w (DE-627)NLM239775449 |x 1942-2962 |7 nnns |
| 773 | 1 | 8 | |g volume:13 |g year:2020 |g number:2 |g day:06 |g month:05 |g pages:72-73 |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 13 |j 2020 |e 2 |b 06 |c 05 |h 72-73 | ||